By Associate Professor Anthony Michael Joshua

Conference Papers

Allen IA; Russell A; Jackson KJ; Peters T; Gibson G; Joshua AM; Goodnow CC; Burnett DL; Barnet MB, 2022, 'Correlation between a CTLA-4 single nucleotide polymorphism and high response to anti-PD1/PDL1 immunotherapy in advanced non small cell lung cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892509504367&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mak B; Lin H-M; Kwan E; Fettke H; Tran B; Davis I; Mahon K; Stockler M; Briscoe K; Marx G; Tan W; Huynh K; Du P; Yu J; Jia S; Joshua A; Kohli M; Meikle P; Azad A; Horvath L, 2021, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 48 - 49, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000705028800031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ardolino L; Joshua A; Horvath L; Mahon K; Mak B; Fizazi K; Sommer GS; Carles J; Sim H-W, 2021, 'The influence of concurrent lipid modifying medications in men receiving docetaxel or cabazitaxel for mCRPC - A meta-analysis of the FIRSTANA, PROSELICA, TAX-327 and TROPIC studies', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 68 - 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000705028800065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Piperno-Neumann S; Hassel JC; Rutkowski P; Baurain J-F; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Nathan P, 2021, 'Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, http://dx.doi.org/10.1158/1538-7445.am2021-ct002

Hofman M; Emmett L; Iravani A; Sandhu S; Joshua A; Pattison D; Goh J; Kirkwood I; Tan TH; Francis R; Ng S; Rutherford N; Gedye C; Scott A; Lee S-T; Weickhardt A; Ramdave S; Kwan E; Azad A; Macdonald W; Redfern A; Zhang A; Stockler M; Martin A; Davis I, 2021, 'Lu-177-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, ELECTR NETWORK, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), ELECTR NETWORK, 12 June 2021 - 15 June 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600793&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Shenderov E; Mallesara GHG; Wysocki PJ; Xu W; Ramlau R; Weickhardt AJ; Zolnierek J; Spira A; Joshua AM; Powderly J; Antonarakis ES; Jang S; Aragon-Ching J; Shen J; Paller C; Vogelzang NJ; Leu K; Cortes J; Bohac C; Lugowska I, 2021, 'MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion', in ANNALS OF ONCOLOGY, ELSEVIER, pp. S657 - U246, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000700527701084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jamal S; Nagrial A; Joshua A; Eek R; Jamal S, 2020, 'PHASE 1/2 STUDY USING ENB-003, A FIRST-IN-CLASS SELECTIVE ETBRI, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMORS', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A480 - A481, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0803

Marastoni S; Pesic A; Nair SN; Li ZJ; Madani A; Haibe-Kains B; Wouters BG; Joshua A, 2020, 'Targeting lysosomal homeostasis in ovarian cancer through drug repurposing', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-3401

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302345&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Alibhai SMH; Breunis H; Timilshina N; Hansen AR; Joshua AM; Warde PR; Gregg RW; Fleshner NE; Tomlinson G; Hotte SJ; Emmenegger U, 2020, 'The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900143&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Schmidt AL; Anton A; Wong SS; Azad A; Kwan EM; Spain LA; Torres J; Muthusamy A; Parente P; Parnis F; Goh JC; Joshua AM; Pook DW; Gibbs P; Tran B; Weickhardt AJ, 2020, 'Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barnet M; Pathmanandavel S; McCarthy L; Goodnow C; Joshua A, 2019, 'The Australian Exceptional Responders Program: A national collaboration', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295505242&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rose AAN; Armstrong SM; Hogg D; Butler M; Joshua AM; Ghazarian D; Kamel-Reid S; Habeeb AA; Chappell MA; Ross K; Amir E; Bedard PL; Siu L; Spreafico A, 2019, 'Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma', in Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-3141

Gurney H; Massard C; Retz M; Tafreshi A; Carles J; Hammerer P; Fong PCC; Shore ND; Joshua AM; Linch MD; Romano E; Augustin M; Piulats J; Quevedo F; Berry WR; Kolinsky MP; Sridhar SS; Conter HJ; Drakaki A; Feyerabend S; Appleman LJ; Wu H; Schloss C; Poehlein CH; De Bono JS; Yu EY, 2019, 'List of Poster Abstracts', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 31 - 32, http://dx.doi.org/10.1111/ajco.13228

Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG, 2019, 'Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Joshua A; Epstein R; Chalasani V; Kneebone A; Hruby G; O'Neill G; Stricker P; Stricker P; Quoc N; Ho B, 2018, 'Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), PA, Philadelphia, 23 June 2018 - 26 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000467489900093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Crumbaker M; Joshua AM; Epstein R; Emmett L, 2018, 'A phase I study of Lu-177-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088

Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TRJ; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P, 2018, 'Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)', in Journal of Clinical Oncology, pp. 1232 - 1239, http://dx.doi.org/10.1200/JCO.2017.74.1090

Ernst DS; Petrella T; Joshua A; Cheng T; Smylie M; Baetz T; Hamou A; Gwadry-Sridhar F, 2016, 'Impact of ipilimumab on metastatic melanoma: Evaluation using patient registry in Canada', in Annals of Oncology, pp. vi384, http://dx.doi.org/10.1093/annonc/mdw379.17

Corfield J; Crozier J; Joshua A; Bolton D; Lawrentschuk N, 2016, 'Understanding the role of new systemic agents in the treatment of prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 12 - 12, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381708200019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Manders P; Joshua AM; Kefford R; Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Hersey P; Li XN; Diede SJ; Ebbinghaus S; Hodi FS, 2016, 'THREE-YEAR OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED MELANOMA TREATED WITH PEMBROLIZUMAB IN KEYNOTE-001', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380005100012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Samadian S; Bavi P; Chadwick D; Danesh A; Dowar M; Li T; Siva M; Roehl M; Joshua AM; Pugh TJ, 2016, 'Abstract 167: Inferring subclonal relationships between multiple metastases from rapid autopsy of a single melanoma patient', in Cancer Research, American Association for Cancer Research (AACR), pp. 167 - 167, http://dx.doi.org/10.1158/1538-7445.am2016-167

Daud A; Joshua AM; Ribas A; Robert C; Hodi FS; Wolchok J; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Kefford R; Lindia J; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'A POOLED ANALYSIS OF 655 PATIENTS WITH ADVANCED MELANOMA ENROLLED IN KEYNOTE-001: LONG-TERM EFFICACY OF PEMBROLIZUMAB (MK-3475)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 43 - 43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Puts M; Sattar S; McWatters K; Lee K; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Jang RW-J; Alibhai SMH, 2015, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036904893&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Robert C; Joshua AM; Kefford R; Joseph RW; Wolchok JD; Hodi FS; Hamid O; Weber JS; Gangadhar TC; Dronca RS; Patnaik A; Zarour HM; Hwu W-J; Hersey P; Daud A; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Ribas A, 2015, 'Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901960&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Zarour HM; Kefford R; Loboda A; Albright A; Kang SP; Ebbinghaus S; Yearley J; Murphy E; Nebozhyn M; Lunceford JK; McClanahan T; Ayers M; Daud A, 2015, 'Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.3001

Wolchok JD; Hamid O; Ribas A; Robert C; Kefford R; Hwu W-J; Weber JS; Joshua AM; Gangadhar TC; Dronca RS; Daud A; Patnaik A; Joseph RW; Zarour HM; Li XN; Xue D; Ebbinghaus S; Kang SP; Perrone AM; Hodi FS, 2015, 'Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.3000

Beer TM; Armstrong AJ; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; Saad F; Joshua AM; De Bono JS; Venner PM; Carles J; Mainwaring PN; Evans CP; Parli T; Mansbach HH; Bhattacharya S; Van Os S; Phung D; Tombal BF, 2015, 'Enzalutamide (ENZA) in men with chemotherapy-Naive metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ribas A; Wolchok JD; Robert C; Kefford R; Hamid O; Daud A; Hwu W-J; Weber JS; Joshua AM; Gangadhar TC; Patnaik A; Hersey P; Dronca R; Zarour H; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Hodi FS, 2015, 'UPDATED CLINICAL EFFICACY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) IN 411 PATIENTS WITH MELANOMA', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, PEOPLES R CHINA, Shanghai, pp. E24 - E24, presented at 7th Annual Asian Oncology Summit / 11th Annual Conference of the Organisation-for-Oncology-and-Translational-Research, PEOPLES R CHINA, Shanghai, 10 April 2015 - 12 April 2015, http://dx.doi.org/10.1016/j.ejca.2015.06.072

Bavi P; Siva M; Buany J; Joshua A; Roehrl M, 2015, 'A Cancer Center's Large-Scale Rapid (Warm) Autopsy Program: Unique Insights Into Tumor Kinetics and Biology', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348948000004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Al-Faraidy N; Deodhare N; Naert K; Joshua A; Hogg D; Butler M; Kamel-Reid S; Alhabeeb A; Ghazarian D, 2015, 'Molecular Profiling of Common Melanoma Mutations A Large Cohort Study', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 510A - 511A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348948003549&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Abi-Saab T; Bavi P; Jiang J; Siva M; Chadwick D; Joshua A; Roehrl M, 2015, 'The Effect of Time Between Patient Death and Tissue Collection on RNA Integrity of Metastatic Tumors', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348948000002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Leibowitz-Amit R; Pintille M; Laird AD; Aftab DT; Berger R; Chi KN; Joshua AM, 2015, 'Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trials', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.196

Hotte SJ; Joshua AM; Torri V; Macfarlane RJ; Basappa NS; Powers J; Winquist E; Mukherjee S; Gregg RW; Kollmannsberger CK; Finch DL; Xu H; Hausman DF; Seymour L; Eisenhauer EA; Chi KN, 2015, 'IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.279

Bavi P; Siva M; Butany J; Joshua A; Roehrl M, 2015, 'A Cancer Center's Large-Scale Rapid (Warm) Autopsy Program: Unique Insights Into Tumor Kinetics and Biology', in MODERN PATHOLOGY, SPRINGERNATURE, Boston, MA, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349502200004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Al-Faraidy N; Deodhare N; Naert K; Joshua A; Hogg D; Butler M; Kamel-Reid S; Alhabeeb A; Ghazarian D, 2015, 'Molecular Profiling of Common Melanoma Mutations - A Large Cohort Study', in MODERN PATHOLOGY, SPRINGERNATURE, Boston, MA, pp. 510A - 511A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349502203246&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Abi-Saab T; Bavi P; Jiang J; Siva M; Chadwick D; Joshua A; Roehrl M, 2015, 'The Effect of Time Between Patient Death and Tissue Collection on RNA Integrity of Metastatic Tumors', in MODERN PATHOLOGY, SPRINGERNATURE, Boston, MA, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349502200002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daud A; Hamid O; Robert C; Hodi FS; Wolchok JD; Hwu WJ; Weber JS; Kefford R; Hersey P; Joshua AM; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Gerigich K; Lunceford J; Emacipator K; Dolled-Filhart M; Li X; Kang P; Ebbinghaus S; Ribas A, 2014, 'Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 48 - 49, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70266-7

Khoja L; Kurtz G; Zadeh G; Laperriere N; Menard C; Millar B-A; Bernstein M; Kongkham P; Joshua A; Hogg D; Butler M; Chung C, 2014, 'INCREASED ACUTE RADIATION EFFECT (ARE) WITH IPILUMUMAB AND RADIOSURGERY IN PATIENTS WITH MELANOMA BRAIN METASTASES', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, http://dx.doi.org/10.1093/neuonc/nou240.16

Robert C; Joshua AM; Weber JS; Ribas A; Hodi FS; Kefford RF; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Dronca R; Zarour H; Ge Y; Lindia JA; Giannotti M; Ebbinghaus S; Kang SP; Hamid O, 2014, 'PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 39th ESMO Congress (ESMO), SPAIN, Madrid, 26 September 2014 - 30 September 2014, http://dx.doi.org/10.1093/annonc/mdu438.42

Kefford R; Hamid O; Robert C; Ribas A; Wolchock JD; Hodi FS; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber J; Joseph R; Gergich K; Li X; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma', in BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, SCOTLAND, Edinburgh, pp. 44 - 44, presented at 15th World Congress on Cancers of the Skin, SCOTLAND, Edinburgh, 03 September 2014 - 06 September 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342680900098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kefford R; Hamid O; Robert C; Ribas A; Wolchock JD; Hodi FS; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber J; Joseph R; Gergich K; Li X; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma', in BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, SCOTLAND, Edinburgh, pp. E56 - E56, presented at 15th World Congress on Cancers of the Skin, SCOTLAND, Edinburgh, 03 September 2014 - 06 September 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344006900098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ribas A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Hersey P; Weber JS; Dronca RS; Zarour HM; Gergich K; Li XN; Lannone R; Kang SP; Ebbinghaus S; Robert C, 2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2014.32.18_suppl.lba9000

Leibowitz-Amit R; Joshua AM; Ezzat S; Bourdeau I; Olney H; Oosting S; Seah J-A; Ruether JD; Chin S; Asa SL; Krzyzanowska MK; Knox JJ, 2014, 'A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.e15621

Joseph RW; Elassaiss-Schaap J; Wolchok JD; Joshua AM; Ribas A; Hodi FS; Hamid M; Robert C; Daud A; Hwu W-J; Kefford R; Hersey P; Weber JS; Patnaik A; De Alwis DP; Perrone AM; Kang SP; Ebbinghaus S; Anderson KM; Gangadhar TC, 2014, 'Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3015

Kefford R; Ribas A; Hamid O; Robert C; Daud A; Wolchok JD; Joshua AM; Hodi FS; Gangedher TC; Hersey P; Weber JS; Dronca RS; Patnaik A; Zarour HM; Dolled-Filhart M; Lunceford J; Emancipator K; Ebbinghaus S; Rang SP; Hwu W-J, 2014, 'Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3005

Alimohamed NS; Leibowitz-Amit R; Templeton AJ; Seah J-A; Vera-Badillo FE; Joshua AM; Knox JJ; Tannock I; Sridhar SS, 2014, 'Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.6550

Hamilton RJ; Li J; Naini V; San Kheoh T; De Porre P; Molina A; Lelbowitz-Amit R; De Bono JS; Scher HI; Ryan CJ; Chi KN; Joshua AM, 2014, 'Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.e16045

Back to profile page